|
| Another week, another scary jobs report. The Labor Department said 5.245 million Americans applied for state unemployment benefits last week, bringing the total in the month since the coronavirus pandemic hit the U.S. economy to 22 million – effectively erasing a decade’s worth of job creation. The latest figures suggest the unemployment rate is now around at least 17%, far higher than the 10% unemployment rate reached at the peak of the last recession. “While today... |
| LSI Industries (NASDAQ: LYTS): LSI Industries shares jumped nearly 26% yesterday after the company announced it had secured $100 million in new business through 2022 from one of its long-standing quick service restaurant customers. “Our recent QSR program award highlights LSI’s strategy to anticipate changing requirements in key vertical markets and lead in the development of n... |
SJM might be a good pandemic bet – but don’t buy it for valueAnother reason value analysis and the contrarian mindset often dovetail very nicely with each other is because while most investors shy away from stocks that are dropping, value investors and contrarians alike start to take them more seriously. It also tends to shade an investor’s perspective when a stock is going up; the longer an upward trend lasts, the more a contrarian begins to doubt the trend will be able to last. That is an attitude that often flies in the face of the herd mentality ... |
| |
|
|
| Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. The company’s lead product candidates for the treatment of CF include PTI-801, a third generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Read More |
Other Top Stories |
| |
Trend Following PicksAll Picks |
Reversal PicksAll Picks |
Already subscribed to our premium service?Click here to Login.Not a TradersPro subscriber yet?Learn More About TradersPro Here - Learn The # 1 Key To Successful Stock Investing Profits |
This email was sent to phanphuongthanh89.822152@blogger.com by Investiv, LLC
Forward to a friend | Unsubscribe or Mange which emails you get from TradersPro
Investing is Inherently Risky
There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.
Hypothetical Results Are Reported
Results and examples used in the Company's advertisements, books, videos, websites, and other media—including on the Site and the Network—are, in some cases, based on hypothetical (simulated) trades. Plainly speaking, these trades were not actually executed. Hypothetical performance results have certain limitations. Unlike an actual performance record, hypothetical results do not represent actual trading. Also, since the trades have not been executed, the hypothetical results may have under-or-over compensation for the impact, if any, of certain market factors, such as lack of liquidity. Hypothetical trading programs generally are also subject to the fact that they are designed with the benefit of hindsight. Hypothetical results also do not account for commissions or slippage.
The Company's simulations assume purchase and sale prices believed to be attainable. Yet traders are going to be getting into trades at different times and using various exit approaches, which may result in different pricing and outcomes. You may or may not receive the best available price on the purchase or the sale of a position in actual trading.
Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Company's software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.
Offers Disinterested Commentary and Analysis
The Company does not receive any form of payment or other compensation for publishing information, news, research, or any other material concerning specific securities on the Network that is intended to affect or influence the value of securities. The Company, and its personnel, do not engage in front-running of recommendations and do not trade against one's own recommendations.
The Company and its management may benefit from an increase or decrease in the share prices of the profiled companies, and/or may have other actual or potential conflicts of interest. If a particular security featured in a newsletter publication is concurrently owned by the Company in its corporate brokerage account, or in any of the individual accounts of the Company's principals or analysts / writers, that fact will be disclosed. The Company, its principals, analysts and writers may choose to purchase a security or derivative featured in one of its newsletter publications, but typically will wait three (3) trading days from the date of publication before initiating said purchase.
Disclaimers, Terms & Conditions | Privacy Policy
Copyright © 2019
No comments:
Post a Comment